New medicines for triple negative breast cancer
Small molecules targeting RuvBL complex for triple negative breast cancer
This project aims to create new small molecule medicines for triple negative breast cancer by focusing on how these cancer cells repair their DNA.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11123151 on NIH RePORTER |
What this research studies
Triple negative breast cancer (TNBC) is a challenging type of breast cancer because it lacks the common targets for hormone therapy or HER2-targeted drugs. These cancer cells often have a lot of DNA damage, but they also have very efficient ways to repair this damage, which helps them survive. This research explores a new strategy to stop these cancer cells from repairing their DNA, making them more vulnerable. By targeting these specific repair pathways, the hope is to develop treatments that harm cancer cells while leaving healthy cells alone. We are working to understand and improve a new compound that can block these repair mechanisms.
Who could benefit from this research
Good fit: This foundational research is focused on understanding and developing new treatments for individuals diagnosed with triple negative breast cancer.
Not a fit: Patients without triple negative breast cancer would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this research could lead to new and more effective treatment options for patients with triple negative breast cancer.
How similar studies have performed: This project builds upon a recently identified novel compound, indicating it is an early-stage but promising new approach.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Xiao, Xiangshu — Oregon Health & Science University
- Study coordinator: Xiao, Xiangshu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.